Breast Cancer Clinical Trials

Showing 481-500 of 5,597 trials

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

NCT02860000

This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may be better in treating patients with breast cancer.

Estrogen Receptor StatusHER2/Neu NegativeInvasive Breast Carcinoma+6 more

Mayo Clinic96 participantsStarted Jul 2017

Washington D.C., District of Columbia, United States • Boston, Massachusetts, United States • Ann Arbor, Michigan, United States +5 more locations

RECRUITINGPhase 2

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

NCT03808337

This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

Triple Negative Breast CancerNon Small Cell Lung CancerMetastatic Breast Cancer+1 more

Memorial Sloan Kettering Cancer Center145 participantsStarted Jan 2019

San Carlos, California, United States • Hartford, Connecticut, United States • Norwalk, Connecticut, United States +9 more locations

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Related Searches

2D:4D Finger Ratio and Breast Cancer in Women

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.

Testing Conversation Aid in Practice

Video Education With Result Dependent dIsclosure

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Rehabilitation for People With Advanced Cancer

Rash & Diarrhea Prophylaxis With Capivasertib

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer